Intestinal gas can help diagnose diseases: Study

These systems may offer a reliable way to understand the impact of intestinal gases on human health

<a href="http://www.shutterstock.com/pic-136518497/stock-photo-girl-student-holding-a-microtube.html" target="_blank">Clinical Trial</a> image via Shutterstock
IANS Melbourne
Last Updated : Mar 13 2015 | 2:48 PM IST

Throwing fresh insight on how microbes affect our health, a new study reveals that gut microbes in human body produce gases that may contribute to gastrointestinal diseases and could be used as biomarkers for one's state of health.

Microbes in our body are estimated to outnumber human cells by 10 to 1, still research on how they affect health is still in its infancy.

"The human gut's effect on gastrointestinal diseases consumes a significant portion of health care expenditure every year worldwide," said Kourosh Kalantar-zadeh, professor of electrical and computer engineering at RMIT University, Melbourne and senior author.

To measure these potential biomarkers, researchers suggest two novel gas-sensing systems, one of which is an electronic gas sensor in the form of a pill you can swallow.

These systems may offer a reliable way to understand the impact of intestinal gases on human health.

This may also pave the way for the development of new diagnostic techniques and therapies.

"Innovative point-of-care methodologies for assessing gut state and diagnosing relevant diseases will bring unprecedented benefits to the general public by providing medical and diagnostic devices that significantly reduce medical costs and improve the efficiency of the health care system," Kalantar-zadeh pointed out.

In-vitro fermentation systems and swallowable gas capsules represent promising alternatives, showed the authors.

A more direct and accurate approach involves the use of encapsulated gas sensors that can be swallowed and sample gases while inside the intestine.

"Because both techniques are noninvasive, they have the potential to significantly impact relevant medical industries and public health sectors, facilitating the formulation of point-of-care methodologies for diagnostics and potentially new diet- or drug-based therapies for gastrointestinal diseases," Kalantar-zadeh concluded.

The study appeared in the journal Cell Press.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 13 2015 | 2:12 PM IST

Next Story